Affymetrix Board Rebuffs Origin's Second Offer, Reaffirms Support for Thermo Fisher Merger | GenomeWeb

NEW YORK (GenomeWeb) – Affymetrix's board of directors today dismissed the most recent bid by Origin Technologies to acquire Affy for $17.00 per share in an all-cash transaction, reaffirming its support for a previously approved merger agreement with Thermo Fisher Scientific at $14 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.